Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
Antibody-Dependent Cell Cytotoxicity
/ drug effects
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
B-Lymphocytes
/ drug effects
CD8-Positive T-Lymphocytes
/ drug effects
Cell Proliferation
/ drug effects
Cyclophosphamide
/ therapeutic use
Cytokines
/ biosynthesis
Doxorubicin
/ therapeutic use
Drug Resistance, Neoplasm
/ immunology
Humans
Immunological Synapses
/ drug effects
Immunotherapy
/ methods
Killer Cells, Natural
/ drug effects
Lenalidomide
/ administration & dosage
Lymphocyte Activation
/ drug effects
Lymphocyte Count
Lymphoma, Follicular
/ drug therapy
Neutrophils
/ drug effects
Prednisone
/ therapeutic use
Rituximab
/ administration & dosage
Tumor Cells, Cultured
Vincristine
/ therapeutic use
antibody-dependent cell-mediated cytotoxicity
follicular lymphoma
immunomodulation
lenalidomide
non-Hodgkin lymphoma
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
03
12
2018
accepted:
14
12
2018
pubmed:
16
2
2019
medline:
6
5
2020
entrez:
16
2
2019
Statut:
ppublish
Résumé
Chemotherapy plus rituximab has been the mainstay of treatment for follicular lymphoma (FL) for two decades but is associated with immunosuppression and relapse. In phase 2 studies, lenalidomide combined with rituximab (R
Identifiants
pubmed: 30767211
doi: 10.1111/bjh.15797
pmc: PMC6594227
doi:
Substances chimiques
Cytokines
0
R-CHOP protocol
0
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Lenalidomide
F0P408N6V4
Prednisone
VB0R961HZT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
240-253Informations de copyright
© 2019 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Ann Oncol. 2003 Jan;14(1):171-2
pubmed: 12488313
N Engl J Med. 2004 Nov 18;351(21):2159-69
pubmed: 15548776
Ann Oncol. 2007 Jul;18(7):1209-15
pubmed: 17496307
J Clin Invest. 2008 Jul;118(7):2427-37
pubmed: 18551193
Clin Cancer Res. 2008 Jul 15;14(14):4650-7
pubmed: 18628480
Am J Hematol. 2009 Sep;84(9):553-9
pubmed: 19565649
Blood. 2009 Nov 19;114(21):4713-20
pubmed: 19786615
Leukemia. 2012 Nov;26(11):2326-35
pubmed: 22552008
Clin Adv Hematol Oncol. 2012 Dec;10(12):810-8
pubmed: 23271353
Lancet. 2013 Apr 6;381(9873):1203-10
pubmed: 23433739
Leuk Res. 2013 Oct;37(10):1213-5
pubmed: 23968916
Br J Haematol. 2014 Mar;164(6):811-21
pubmed: 24328678
Blood. 2014 May 8;123(19):2944-52
pubmed: 24591201
Br J Haematol. 2014 May;165(3):375-81
pubmed: 24606326
Ann Hematol. 2014 Nov;93(11):1879-87
pubmed: 24951124
Nat Struct Mol Biol. 2014 Sep;21(9):803-9
pubmed: 25108355
Haematologica. 2015 Jan;100(1):77-86
pubmed: 25344523
Lancet Oncol. 2014 Nov;15(12):1311-8
pubmed: 25439689
Blood. 2015 Jul 2;126(1):50-60
pubmed: 26002964
Blood. 2015 Aug 6;126(6):779-89
pubmed: 26002965
Lancet Oncol. 2015 Sep;16(9):1111-1122
pubmed: 26256760
J Clin Oncol. 2015 Nov 1;33(31):3635-40
pubmed: 26304886
Leuk Lymphoma. 2016;57(4):880-7
pubmed: 26379040
Blood Cancer J. 2015 Oct 23;5:e362
pubmed: 26495859
Haematologica. 2016 May;101(5):e196-9
pubmed: 26858355
Haematologica. 2016 Oct;101(10):1244-1250
pubmed: 27354024
CA Cancer J Clin. 2016 Nov 12;66(6):443-459
pubmed: 27618563
Oncology. 2016;91(6):302-310
pubmed: 27682623
Oncoimmunology. 2016 Aug 24;5(10):e1224044
pubmed: 27990323
Br J Haematol. 2017 Jul;178(2):250-256
pubmed: 28419413
Br J Haematol. 2017 Nov;179(3):399-409
pubmed: 28771673
Blood. 2017 Sep 28;130(13):1491-1498
pubmed: 28784599
Ann Oncol. 2017 Nov 1;28(11):2806-2812
pubmed: 28945884
Am J Hematol. 2018 Jan;93(1):E1-E3
pubmed: 28960532
Am J Hematol. 2018 Feb;93(2):296-305
pubmed: 29314206
Oncoimmunology. 2017 Dec 20;7(4):e1409322
pubmed: 29632722
N Engl J Med. 2018 Sep 6;379(10):934-947
pubmed: 30184451
J Clin Oncol. 2019 Jan 10;37(2):144-152
pubmed: 30481079